公开(公告)号：US11261482B2

公开(公告)日：2022-03-01

申请号：US16304340

申请日：2017-05-25

Applicant: GENCURIX INC.

Inventor： Young Kee Shin ,  Bohyun Byun ,  Hyunjeung Choi ,  Joon Seok Choi ,  Young Ho Moon ,  Jong Heun Lee ,  Sang Rea Cho ,  Jee Eun Kim ,  Myungsun Kim

IPC: C12Q1/68 ,  C07H21/04 ,  C12Q1/6827 ,  C12Q1/6823 ,  C12Q1/686 ,  C12Q1/6874 ,  C12Q1/6886

Abstract: The present invention relates to a composition for detecting an epidermal cell growth factor receptor gene mutation and to a kit comprising the composition and, more specifically, to a primer and probe set composition for detecting an epidermal cell growth factor gene mutation, and to a kit for detecting an EGFR gene mutation, comprising the composition. A method according to the present invention can not only predict and diagnose responsiveness to a therapeutic agent for the prognosis of a cancer patient, but also predict a cancer metastasis or relapse Thus, the method can be useful for the purposes of determining the need to administer an anticancer therapeutic agent and guiding the direction of future treatment, and for monitoring a cancer metastasis or relapse.

公开(公告)号：US10718030B2

公开(公告)日：2020-07-21

申请号：US15938331

申请日：2018-03-28

Applicant: GENCURIX INC.

Inventor： Sang Rae Cho ,  Young Ho Moon ,  Jin Il Han ,  Young Kee Shin

IPC: C12Q1/6886 ,  C12Q1/68 ,  C12P19/34

Abstract: The present invention relates to a method of predicting the effectiveness of chemotherapy in a breast cancer patient, and more particularly, to a method for predicting the effectiveness of chemotherapy by measuring the expression levels of genes for predicting prognosis of breast cancer and a standard gene in a biological sample obtained from the breast cancer patient, and a method for predicting the difference between a patient group having a high effectiveness of chemotherapy and a patient group having a low effectiveness of chemotherapy.Therefore, the method of the present invention can accurately predict the effectiveness of chemotherapy for the breast cancer patient, and can be used for the purpose of presenting clues about the direction of breast cancer treatment in the future.

公开(公告)号：US10428386B2

公开(公告)日：2019-10-01

申请号：US15285194

申请日：2016-10-04

Applicant: Gencurix Inc.

Inventor： Young Kee Shin ,  Young-Deug Kim ,  En Sel Oh ,  Si Eun Kim

IPC: C12Q1/68 ,  C12Q1/6886 ,  G16B25/00 ,  G01N33/574

Abstract: The present invention relates to a method for selecting a gene intended to predict the prognosis for a cancer, to the selected gene for predicting the prognosis of cancer and to a kit for predicting and a method for predicting metastasis in breast-cancer patients by using the same. In the present invention, a straight forward method is used to achieve high-reliability prediction of the patient's prognosis by analyzing for the genetic characteristics of early stage breast cancer, and thus the present invention can be used to advantage in prognosis diagnosis which can reduce unnecessary anticancer therapy.

公开(公告)号：US11840733B2

公开(公告)日：2023-12-12

申请号：US16462655

申请日：2017-11-21

Applicant: GENCURIX INC.

Inventor： Sang Rae Cho ,  Young Ho Moon ,  Jin Il Han ,  Young Kee Shin

IPC: C12Q1/6886

CPC classification number: C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/158

Abstract: The present invention relates to a method for predicting the prognosis of a breast cancer patient. More specifically, to provide information needed to predict the prognosis of a breast cancer patient, the method for predicting the prognosis of breast cancer including the following steps of the present invention comprises: (a) obtaining a biological sample from a breast cancer patient; (b) measuring the mRNA expression level of matrix metallopeptidase 11 (MMP11) and the mRNA expression level of cluster of differentiation 2 (CD2) from patient information or the sample of step (a); (c) normalizing the gene mRNA expression levels selected and measured in step (b); and (d) predicting the prognosis of breast cancer by combining the gene expression levels normalized in step (c), wherein overexpression of the MMP11 indicates a bad prognosis, and overexpression of CD2 indicates a good prognosis.
The method of the present invention has an effect of being capable of more accurately predicting the future prognosis of metastasis, recurrence, or metastatic recurrence in breast cancer patients, and in particular, has a very excellent ability to predict the prognosis of HER2-type breast cancer, the prognosis of which is very poor, and thus can be usefully used to provide clues for the direction of future treatment of breast cancer.

公开(公告)号：US20130344482A1

公开(公告)日：2013-12-26

申请号：US13935502

申请日：2013-07-04

Applicant: Gencurix Inc.

Inventor： Young Kee Shin ,  Yoon La Choi ,  Young-Deug Kim ,  Eu Sel Oh ,  Si Eun Kim

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N33/57415 ,  G01N33/57484 ,  G01N2333/723 ,  G16B25/00

Abstract: The present invention relates to a method for selecting a gene intended to predict the prognosis for a cancer, to the selected gene for predicting the prognosis of cancer and to a kit for predicting and a method for predicting metastasis in breast-cancer patients by using the same. In the present invention, a straight forward method is used to achieve high-reliability prediction of the patient's prognosis by analysing for the genetic characteristics of early stage breast cancer, and thus the present invention can be used to advantage in prognosis diagnosis which can reduce unnecessary anticancer therapy.

Abstract translation: 本发明涉及选择用于预测癌症预后的基因的方法，所选择的用于预测癌症预后的基因和用于预测的试剂盒和用于预测乳腺癌患者转移的方法的方法，所述方法通过使用 相同。 在本发明中，通过分析早期乳腺癌的遗传特征，使用直接法来实现患者预后的高可靠性预测，因此本发明可以用于预后诊断中，可以减少不必要的 抗癌治疗。

公开(公告)号：US11220716B2

公开(公告)日：2022-01-11

申请号：US15938633

申请日：2018-03-28

Applicant: GENCURIX INC.

Inventor： Sang Rae Cho ,  Young Ho Moon ,  Jin Il Han ,  Young Kee Shin

IPC: C12Q1/6886 ,  C12Q1/68

Abstract: The present invention relates to a method of predicting the effectiveness of chemotherapy in a breast cancer patient, and more particularly, to a method for predicting the effectiveness of chemotherapy by measuring the expression levels of genes for predicting prognosis of breast cancer and a standard gene in a biological sample obtained from the breast cancer patient, and a method for predicting the difference between a patient group having a high effectiveness of chemotherapy and a patient group having a low effectiveness of chemotherapy.
Therefore, the method of the present invention can accurately predict the effectiveness of chemotherapy for the breast cancer patient and can be used for the purpose of presenting clues about the direction of breast cancer treatment in the future.

公开(公告)号：US11107552B2

公开(公告)日：2021-08-31

申请号：US16129206

申请日：2018-09-12

Applicant: ABION, INC. ,  GENCURIX INC.

Inventor： Young Kee Shin ,  Mi Jeong Kwon ,  En Sel Oh ,  Yong Ho In ,  Sang Seok Koh

IPC: C12Q1/6851 ,  G16B25/00 ,  C12Q1/6813

Abstract: Disclosed are data processing and analysis methods for gene expression data for identifying endogenous reference genes and a composition for the quantitative analysis of gene expression, comprising a pair of primers and/or probes useful in amplifying the identified endogenous reference genes. Introduced with the concepts of “Zero's proportion” and CV, the method allows different datasets to be integrally analyzed, thereby searching for novel reference genes. By the method, 2,087 genes are first found as housekeeping genes which are expressed in most tissues, and the usefulness thereof in the relative quantification of different target genes is determined by analyzing their expression stability. Of the 2,087 genes, 13 genes show higher expression stability with lower expression levels across a wide range of samples than traditional reference genes such as GAPDH and ACTS, and therefore are suitable for the normalization of universal genes having relatively low expression levels.

公开(公告)号：US20190012429A1

公开(公告)日：2019-01-10

申请号：US16129206

申请日：2018-09-12

Applicant: ABION, INC. ,  GENCURIX INC.

Inventor： Young Kee Shin ,  Mi Jeong Kwon ,  En Sel Oh ,  Yong Ho In ,  Sang Seok Koh

IPC: G06F19/20 ,  C12Q1/6813 ,  C12Q1/6851

Abstract: Disclosed are data processing and analysis methods for gene expression data for identifying endogenous reference genes and a composition for the quantitative analysis of gene expression, comprising a pair of primers and/or probes useful in amplifying the identified endogenous reference genes. Introduced with the concepts of “Zero's proportion” and CV, the method allows different datasets to be integrally analyzed, thereby searching for novel reference genes. By the method, 2,087 genes are first found as housekeeping genes which are expressed in most tissues, and the usefulness thereof in the relative quantification of different target genes is determined by analyzing their expression stability. Of the 2,087 genes, 13 genes show higher expression stability with lower expression levels across a wide range of samples than traditional reference genes such as GAPDH and ACTS, and therefore are suitable for the normalization of universal genes having relatively low expression levels.

公开(公告)号：US11970732B2

公开(公告)日：2024-04-30

申请号：US16500549

申请日：2018-04-04

Applicant: GENCURIX INC. ,  LOGONE BIO CONVERGENCE RESEARCH FOUNDATION

Inventor： Young Kee Shin ,  Jin Ju Kim ,  Sung Su Kim ,  Hyun Jeung Choi ,  Young Ho Moon ,  Myung Sun Kim ,  Jee Eun Kim

IPC: C12Q1/68 ,  C12Q1/686

CPC classification number: C12Q1/686

Abstract: The present invention relates to a method for determining the DNA quality of a biological sample and, more specifically, to a method for determining the DNA quality of a biological sample by performing a quantitative polymerase chain reaction (PCR) using primers capable of amplifying a target gene, a method for preparing the primers used in the method, and a method for standardizing the amount of detected target gene mutation by using the determined DNA quality. The method of the present invention enables objective evaluation of the DNA quality of a biological sample used in gene analysis and the presentation of objective results on the expression ratio of a gene mutation, thereby providing reliable information in the fields of clinical research and companion diagnosis.

公开(公告)号：US10655187B2

公开(公告)日：2020-05-19

申请号：US16155220

申请日：2018-10-09

Applicant: GENCURIX INC.

Inventor： Young Kee Shin ,  Young-Deug Kim ,  En Sel Oh ,  Jun Young Choi ,  Sang Rea Cho

IPC: C07H21/04 ,  C12Q1/68 ,  C12Q1/6886

Abstract: The present invention relates to a gene for predicting or diagnosing the prognosis of early-stage breast cancer and to a use thereof, and more specifically relates to a genetic marker for predicting or diagnosing the prognosis of breast cancer, including TRBC1 (T cell receptor beta constant 1), BTN3A2 (butyrophilin, subfamily 3, member A2) or HLA-DPA1 (major histocompatibility complex, class II, DP alpha 1) for providing information necessary for predicting or diagnosing the prognosis of a breast cancer patient. The genetic marker of the present invention allows the prediction or diagnosis of the prognosis of a breast cancer patient, and can therefore advantageously be used for the purpose of providing a direction as to the future course of breast cancer treatment, including a decision on whether anticancer therapy is necessary.